A Prescription for Precision: Integrating Genetics into Essential Medicines Lists
A new analysis reveals a critical gap in global health policy: essential medicines lists (EMLs) from the WHO and across Africa currently lack pharmacogenomic guidance, potentially leading to sub-optimal treatment outcomes. The study systematically reviewed these lists, finding that on average, one in every eight medicines in a country’s EML has an established, actionable pharmacogenomic biomarker. The most affected drug classes include anti-infectives, immunomodulators, and medicines for mental health.
Continue reading to unlock the full analysis, deeper implications, and why this study may matter for your field.
Unlock Full Briefing — 50% Off with Coupon: ERWMCWYU
Full version includes the complete summary, study significance, and direct link to the original source.
Stay curious. Stay informed — with Science Briefing.
This is a preview briefing. Upgrade to access the full version.
